Already today, pharmaceuticals, biotechnology and medical technology are the country’s largest export products after paper, and if this trend continues, we can look forward to even greater exports and more skilled jobs. But international competition is fierce. What does it take for Sweden to get the follow-up investments and become a long-term manufacturing country for the world’s life science products?<\/p>\n
The seminar will address issues such as:<\/strong><\/p>\n Oscar Stenstr\u00f6m, State Secretary to the Minister for Trade Ann Linde Jan Erneberg, General Manager at GE Healthcare Global Supply Chain Margareta Ozolins, VP Sweden Operations and Head of AstraZeneca’s factories<\/strong>in S\u00f6dert\u00e4lje Kirsti Gjellan, Head of Biologics Development and Supply at Sobi Christopher Siegmund, Site Manager for Pfizer’s Str\u00e4gn\u00e4sfabrik Carl-Johan Sundberg, board member of Cobra Biologics, Professor KI The seminar and discussion will be led by Ingrid Heath, Vice President and Head of Policy at SwedenBIO.<\/strong><\/p>\n\n
Speakers<\/h3>\n
\n<\/strong>The Government’s reindustrialization strategy will help to strengthen industry’s international competitiveness and make investments in Swedish industry more attractive. During the seminar, he will discuss with industry representatives how the initiative will attract life science manufacturing to Sweden.<\/p>\n
\n<\/strong>With an investment of SEK 870 million, GE Healthcare will double its manufacturing capacity in Uppsala over the next three years. Listen to Jan Erneberg talk about the considerations for the decision to locate the investment in Sweden and the plans for the future.<\/p>\n
\n S\u00f6dert\u00e4lje is AstraZeneca’s largest manufacturing site and in the coming years the company is investing over SEK 2 billion in an additional facility.<\/strong> Margareta Ozolins talks about the global trends affecting where future pharmaceutical production will take place and what role AstraZeneca sees Sweden playing.<\/p>\n
\n<\/strong>Sobi’s contract manufacturing of biologics provides a sustainable basis for research and development of the company’s new biologics – both financially and in terms of knowledge. Listen to Kirsti Gjellan <\/strong>on the future of highly specialized pharmaceutical manufacturing and how manufacturing knowledge is crucial for innovation in the field of biologics. <\/em><\/strong><\/p>\n
\n<\/strong>Pfizer is one of the world’s largest pharmaceutical companies and the company’s biotech manufacturing facility in Str\u00e4ngn\u00e4s is one of Northern Europe’s largest in the production of biopharmaceuticals. The company has continuously continued to invest in its Swedish facility, but where in the world the company chooses to place its production is continuously evaluated. Christopher Siegmund, site manager of the Str\u00e4gn\u00e4s factory, explains the factors that determine where the factories end up.<\/p>\n
\n<\/b><\/span>The virtual business culture that characterizes life sciences also affects manufacturing. Cobra Biologics is a Swedish company that specializes in helping smaller companies develop, scale up and manufacture advanced biologics. Listen to Carl-Johan Sundberg, board member of Cobra Biologics and professor at KI, talk about the role of the advanced contract manufacturer in increasing the value of Swedish companies and attracting foreign companies to Sweden.<\/span><\/p>\n